תחזית צמיחת רווחים לשנה הבאה scisparc.com (SPRC)
Demand for pharmaceuticals remains stable, although geopolitics and sanctions complicate raw material logistics. The development of unique cannabinoid treatments for the CNS provides SciSparc Ltd (SPRC) opportunities for market dominance. The target net income per share growth rate reflects the impact of these factors, with the metric holding at 0.00. The company is currently battling a liquidity shortage, cutting expenses due to costly clinical trials.
פילוחים אנליטיים של חברת SciSparc Ltd
The indicator calculates the expected percentage growth of net earnings per share based on consolidated analyst forecasts and current financial reporting data. This metric determines the fairness of the market valuation of SciSparc Ltd (SPRC), where inertial demand for CNS therapy drugs guarantees revenue stability, as reflected in the trend of the company's forward EPS estimates.
